In a groundbreaking partnership, Hengrui Pharma and GSK have entered agreements to jointly develop up to 12 innovative medicines spanning Respiratory, Immunology & Inflammation, and Oncology. This collaboration, which includes a license for a potential best-in-class PDE3/4 inhibitor, marks a significant milestone in the biotech industry. The first participants with obesity or overweight and weight-related comorbidities have already been dosed in a Phase IIa study in the U.S., showcasing the promise of once-monthly subcutaneous depot formulation. Analysts are closely watching Novo Nordisk in what they term a ‘show-me’ phase, anticipating substantial growth numbers. Additionally, a new free trade agreement is poised to ease regulatory burdens on UK exports to India, providing a boost to the biotech sector.
Read more from search.yahoo.com